Myocardial Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy Caused by Mutations in Troponin I

Overview

Journal Heart

Date 2005 Jul 16

PMID 16020591

Citations 31

Authors

J C Moon

J Mogensen

P M Elliott

G C Smith

A G Elkington

S K Prasad

D J Pennell

W J McKenna

Affiliations

Soon will be listed here.

Abstract

Objective: To examine the influence of genotype on late gadolinium enhancement (LGE) and the potential of cardiovascular magnetic resonance (CMR) to detect preclinical hypertrophic cardiomyopathy.

Design: Prospective, blinded cohort study of myocardial LGE in a genetically homogeneous population.

Patients: 30 patients with disease causing mutations in the recognised hypertrophic cardiomyopathy gene for cardiac troponin I (TNNI3): 15 with echocardiographically determined left ventricular hypertrophy (LVH+) and 15 without (LVH-).

Main Outcome Measures: CMR measures of regional left ventricular function, wall thickness, and mass, and the extent and distribution of LGE.

Results: LGE was found in 12 (80%) LVH+ patients but with variable extent (mean 15%, range 3-48%). LGE was also found in two (13%) LVH- patients but the extent was limited (3.6%) and both patients were found to have an abnormal ECG and regional hypertrophy by cine CMR. The extent of LGE was positively associated with clinical markers of sudden death risk (21% with > or = 2 risk factors v 7% with < or = 1 risk factor, p = 0.02) and left ventricular mass (r = 0.56, p < 0.001) and was inversely associated with ejection fraction (r = -0.58, p < 0.001). Segmental analysis showed that as regional wall thickness increased, LGE was more prevalent (p < 0.0001) and more extensive (r = 0.98, p = 0.001).

Conclusion: In patients with disease causing mutations in TNNI3, focal fibrosis was not detected by LGE CMR before LVH and ECG abnormalities were present. Once LVH is present, LGE is common and the extent correlates with adverse clinical parameters. This suggests that focal fibrosis is closely linked to disease development.

Citing Articles

A Case Report on Diagnostic Approach of a Complex Clinical Scenario: Differentiation Between Coronary Artery Disease and Apical Hypertrophic Cardiomyopathy as a Cause of Recurrent Debilitating Angina.

Mahal S, Tarun T, Datta S, Aggarwal K Cureus. 2021; 13(4):e14496.

PMID: 34007749 PMC: 8121130. DOI: 10.7759/cureus.14496.

A case report: Twin sisters with restrictive cardiomyopathy associated with rare mutations in the cardiac troponin I gene.

Ueno M, Takeda A, Yamazawa H, Takei K, Furukawa T, Suzuki Y J Cardiol Cases. 2021; 23(4):154-157.

PMID: 33841591 PMC: 8020042. DOI: 10.1016/j.jccase.2020.10.017.

Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications.

Raman B, Ariga R, Spartera M, Sivalokanathan S, Chan K, Dass S Eur Heart J Cardiovasc Imaging. 2018; 20(2):157-167.

PMID: 30358845 PMC: 6343081. DOI: 10.1093/ehjci/jey135.

The Role of Cardiovascular Magnetic Resonance in Sports Cardiology; Current Utility and Future Perspectives.

Androulakis E, Swoboda P Curr Treat Options Cardiovasc Med. 2018; 20(10):86.

PMID: 30167977 PMC: 6132733. DOI: 10.1007/s11936-018-0679-y.

Delayed Myocardial Enhancement in Pediatric Hypertrophic Cardiomyopathy: Correlation with LV Function, Echocardiography, and Demographic Parameters.

El Saiedi S, Behairy N, Kharabish A, Esmail R, Seliem Z, Shafik M Pediatr Cardiol. 2017; 38(5):1024-1031.

PMID: 28401251 DOI: 10.1007/s00246-017-1612-y.

References

Elliott P, Gimeno Blanes J, Mahon N, Poloniecki J, McKenna W . Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001; 357(9254):420-4. DOI: 10.1016/S0140-6736(00)04005-8. View

Wu E, Judd R, Vargas J, Klocke F, Bonow R, Kim R . Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet. 2001; 357(9249):21-8. DOI: 10.1016/S0140-6736(00)03567-4. View

Varnava A, Elliott P, Mahon N, Davies M, McKenna W . Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 2001; 88(3):275-9. DOI: 10.1016/s0002-9149(01)01640-x. View

Cerqueira M, Weissman N, Dilsizian V, Jacobs A, Kaul S, Laskey W . Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002; 105(4):539-42. DOI: 10.1161/hc0402.102975. View

Marian A . Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol. 2002; 17(3):242-52. PMC: 2775140. View

Choudhury L, Mahrholdt H, Wagner A, Choi K, Elliott M, Klocke F . Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 40(12):2156-64. DOI: 10.1016/s0735-1097(02)02602-5. View

Mogensen J, Kubo T, Duque M, Uribe W, Shaw A, Murphy R . Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest. 2003; 111(2):209-16. PMC: 151864. DOI: 10.1172/JCI16336. View

Moon J, McKenna W, McCrohon J, Elliott P, Smith G, Pennell D . Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003; 41(9):1561-7. DOI: 10.1016/s0735-1097(03)00189-x. View

Kim R, Judd R . Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death?. J Am Coll Cardiol. 2003; 41(9):1568-72. DOI: 10.1016/s0735-1097(03)00190-6. View

10.

Mogensen J, Bahl A, Kubo T, Elanko N, Taylor R, McKenna W . Comparison of fluorescent SSCP and denaturing HPLC analysis with direct sequencing for mutation screening in hypertrophic cardiomyopathy. J Med Genet. 2003; 40(5):e59. PMC: 1735481. DOI: 10.1136/jmg.40.5.e59. View

11.

Maron B, McKenna W, Danielson G, Kappenberger L, Kuhn H, Seidman C . American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the.... J Am Coll Cardiol. 2003; 42(9):1687-713. DOI: 10.1016/s0735-1097(03)00941-0. View

12.

Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S . Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004; 109(10):1284-91. PMC: 2779533. DOI: 10.1161/01.CIR.0000121426.43044.2B. View

13.

Moon J, Reed E, Sheppard M, Elkington A, Ho S, Burke M . The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004; 43(12):2260-4. DOI: 10.1016/j.jacc.2004.03.035. View

14.

Anderson K, Sutton M, Lie J . Histopathological types of cardiac fibrosis in myocardial disease. J Pathol. 1979; 128(2):79-85. DOI: 10.1002/path.1711280205. View

15.

St John Sutton M, Lie J, Anderson K, OBrien P, Frye R . Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br Heart J. 1980; 44(4):433-43. PMC: 482424. DOI: 10.1136/hrt.44.4.433. View

16.

Becker A . Cardiomyopathies with particular reference to the diagnostic relevance of endomyocardial biopsies. Wien Klin Wochenschr. 1988; 100(24):787-91. View

17.

Al-Mahdawi S, Chamberlain S, Chojnowska L, Michalak E, Nihoyannopoulos P, Ryan M . The electrocardiogram is a more sensitive indicator than echocardiography of hypertrophic cardiomyopathy in families with a mutation in the MYH7 gene. Br Heart J. 1994; 72(2):105-11. PMC: 1025469. DOI: 10.1136/hrt.72.2.105. View

18.

Davies M, McKenna W . Hypertrophic cardiomyopathy--pathology and pathogenesis. Histopathology. 1995; 26(6):493-500. DOI: 10.1111/j.1365-2559.1995.tb00267.x. View

19.

Richardson P, McKenna W, Bristow M, Maisch B, MAUTNER B, OConnell J . Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996; 93(5):841-2. DOI: 10.1161/01.cir.93.5.841. View

20.

McKenna W, Spirito P, Desnos M, Dubourg O, Komajda M . Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart. 1997; 77(2):130-2. PMC: 484661. DOI: 10.1136/hrt.77.2.130. View